News | Sudden Cardiac Arrest | August 26, 2022

Genetic Score Detects Those at Risk for Sudden Cardiac Death

New Smidt Heart Institute study, published in JACC, identifies patients at highest risk of experiencing the life-threatening cardiac condition

A new Cedars-Sinai study is the first study proven to be effective at identifying coronary artery disease patients at highest risk for sudden cardiac death. Photo by Cedars-Sinai.

A new Cedars-Sinai study is the first study proven to be effective at identifying coronary artery disease patients at highest risk for sudden cardiac death. Photo by Cedars-Sinai. 


August 26, 2022 — Researchers in the Smidt Heart Institute at Cedars-Sinai are one step closer to identifying patients at highest risk for developing sudden cardiac death—an electrical malfunction in the heart that causes it to stop beating. 

To identify those at highest risk, researchers used a polygenic risk score that has been previously shown successful in predicting coronary artery disease. This Cedars-Sinai study, however, is the first study proven to be effective at identifying coronary artery disease patients at highest risk for sudden cardiac death. 

The study, published today in the Journal of the American College of Cardiology, shows that patients with coronary artery disease without severely impaired heart function had the highest polygenic risk score, translating to a 77% increased risk for sudden cardiac death. 

“In order to better predict and prevent sudden cardiac death, we must first understand the genetic connection between it and coronary artery disease,” said Roopinder Sandhu, MD, MPH,  associate professor of Cardiology, and first author of the study. “We found incorporating information from this genetic risk score improved our ability to predict sudden death beyond the contributions of other known risk markers. Most exciting, the genetics were able to identify patients where sudden death was more likely to limit their life expectancy.” 

Unlike heart attacks (myocardial infarctions), which are typically caused by clogged coronary arteries reducing blood flow to the heart muscle, sudden cardiac death most often results from the sudden onset of erratic electrical activity that impairs the pumping function of the heart. Patients may have little or no warning, and the disorder usually causes death within minutes if no resuscitation is performed. 

Sudden cardiac death—also called sudden cardiac arrest—accounts for approximately 300,000 deaths each year in the U.S. and is a leading international health problem, responsible for 15% to 20% of all deaths. Coronary artery disease is the most common underlying reason for sudden cardiac death. Sandhu says in the future, this work may help better identify patients who would benefit most from lifesaving therapies like a defibrillator. 

At present, most sudden cardiac deaths—70%—occur in patients who do not meet current guidelines for prevention with defibrillator therapy. Thus, contemporary practice not only neglects most individuals who develop sudden cardiac death but also involves electrophysiologists placing defibrillators in patients with advanced heart disease who are often unlikely to benefit due to limited life expectancy. 

The JACC study is based on data from the National Institutes of Health-sponsored PRE-DETERMINE observational study, which has aimed to more accurately identify people at risk for sudden cardiac death among the larger pool of coronary artery disease patients who do not have advanced heart disease. 

Christine Albert, MD, MPH, chair of the Department of Cardiology in the Smidt Heart Institute and senior author, said, “This study indicates there is opportunity to identify patients at highest risk for sudden cardiac death, and then offering meaningful, preventative treatment solutions like a defibrillator. Based on our pivotal research, we now have the foundation to achieve this.”  

For more information: https://www.cedars-sinai.org/ 

 


Related Content

News | Cardiovascular Clinical Studies

January 26, 2023 — A newly-released study extends the understanding of how acquired mutations in blood cells act as a ...

Home January 26, 2023
Home
News | Cardiovascular Clinical Studies

January 24, 2023 — Four cardiology organizations have joined forces in a call to action to reinvent randomized clinical ...

Home January 24, 2023
Home
News | Cardiovascular Clinical Studies

January 11, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies ...

Home January 11, 2023
Home
News | Cardiovascular Clinical Studies

January 3, 2023 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac ...

Home January 03, 2023
Home
News | Cardiovascular Clinical Studies

December 30, 2022 — The Cardiovascular Research Foundation (CRF) recently announced that Alexandra Popma, MD, has joined ...

Home December 30, 2022
Home
News | Cardiovascular Clinical Studies

December 28 2022 — Abiomed announces the United States Food and Drug Administration (FDA) has approved the version of ...

Home December 28, 2022
Home
News | Cardiovascular Clinical Studies

December 27, 2022 — A groundbreaking new clinical trial to determine the effectiveness of a new treatment for patients ...

Home December 27, 2022
Home
News | Cardiovascular Clinical Studies

December 21, 2022 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting ...

Home December 21, 2022
Home
News | Cardiovascular Clinical Studies

December 13, 2022 — A new study by researchers at Intermountain Healthcare in Salt Lake City finds that patients without ...

Home December 13, 2022
Home
News | Cardiovascular Clinical Studies

December 9, 2022 — BioSig Technologies, Inc. an advanced digital signal processing technology company delivering ...

Home December 09, 2022
Home
Subscribe Now